Risk factor comparisons. (A) Nonrelapse mortality. (B) Discontinued systemic treatment. Hazard ratio estimates and 95% confidence limits for each risk factor are shown for patients with chronic GVHD according to NIH criteria (n = 488; solid lines, filled symbols) and for patients who presented initially with late acute GVHD (n = 352; dashed lines, open symbols). Progression to NIH chronic GVHD was treated as a competing risk in the analysis of late acute GVHD, and the analysis of NIH chronic GVHD began when manifestations of GVHD first fulfilled NIH consensus criteria for the diagnosis.